RxDoctor Payments Data

Jessica Olson

Family · Brookfield, WINPI 1346764180

Payments from drug & device makers

$3,417in general payments, 2019–2025

Across 196 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$761
  • Bayer$534
  • AbbVie$502
  • Amgen$279
  • Otsuka America Pharmaceutical, Inc.$278
  • Johnson & Johnson$226
  • plus $837 from 13 others

What the payments were for

  • Food & beverage$3,37099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,417 in reported general payments places this provider in the 90th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,175
Medicare patients
56
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$44,687
FarxigaDapagliflozin Propanediol22$22,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,766
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,082
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen46$1,486
Omeprazole62$1,124
Albuterol Sulfate HfaAlbuterol Sulfate28$1,039
Citalopram HbrCitalopram Hydrobromide20$939
Atorvastatin Calcium138$890
Levothyroxine Sodium100$857
Duloxetine Hcl27$762
Gabapentin32$679
Pantoprazole Sodium44$673
Rosuvastatin Calcium43$583
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$44,68738 claims
AstraZenecaFarxiga$761$22,42422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,273 family providers in Wisconsin.

Other family in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →